BR112016021692A2 - Métodos de preparação de uma composição imunogênica e de aperfeiçoamento de potência imunoestimuladora de vacinas adsorvidas em sal de alumínio, composição imunogênica e uso de uma composição de l(mpla) - Google Patents
Métodos de preparação de uma composição imunogênica e de aperfeiçoamento de potência imunoestimuladora de vacinas adsorvidas em sal de alumínio, composição imunogênica e uso de uma composição de l(mpla)Info
- Publication number
- BR112016021692A2 BR112016021692A2 BR112016021692A BR112016021692A BR112016021692A2 BR 112016021692 A2 BR112016021692 A2 BR 112016021692A2 BR 112016021692 A BR112016021692 A BR 112016021692A BR 112016021692 A BR112016021692 A BR 112016021692A BR 112016021692 A2 BR112016021692 A2 BR 112016021692A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- composition
- mpla
- aluminum salt
- adsorbed
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 9
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 title abstract 3
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969905P | 2014-03-25 | 2014-03-25 | |
| PCT/US2014/045940 WO2015147899A1 (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016021692A2 true BR112016021692A2 (pt) | 2017-08-15 |
Family
ID=51302762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021692A BR112016021692A2 (pt) | 2014-03-25 | 2014-07-09 | Métodos de preparação de uma composição imunogênica e de aperfeiçoamento de potência imunoestimuladora de vacinas adsorvidas em sal de alumínio, composição imunogênica e uso de uma composição de l(mpla) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170165358A1 (enExample) |
| EP (1) | EP3122379A1 (enExample) |
| JP (1) | JP2017509713A (enExample) |
| KR (1) | KR20170016315A (enExample) |
| CN (1) | CN106535929A (enExample) |
| AU (1) | AU2014388299A1 (enExample) |
| BR (1) | BR112016021692A2 (enExample) |
| CA (1) | CA2943050A1 (enExample) |
| MX (1) | MX2016012166A (enExample) |
| RU (1) | RU2016141621A (enExample) |
| SG (2) | SG11201607404PA (enExample) |
| WO (1) | WO2015147899A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113637040A (zh) | 2015-08-19 | 2021-11-12 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
| US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| JP7385206B2 (ja) * | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
| KR20230042053A (ko) | 2020-07-22 | 2023-03-27 | (주)쓰리에이치바이오 | 면역 치료제용 펩타이드 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124013A (zh) * | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
| WO1994019013A1 (en) * | 1993-02-19 | 1994-09-01 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| EP0689454B2 (en) * | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| JP2008530195A (ja) * | 2005-02-16 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | リン酸アルミニウムおよび３ｄ−ｍｐｌを含むアジュバント組成物 |
| CA2687632C (en) * | 2007-05-24 | 2013-01-15 | Glaxosmithkline Biologicals S.A. | Lyophilised antigen composition |
| AU2011231574A1 (en) * | 2010-03-26 | 2012-10-11 | Glaxosmithkline Biologicals S.A. | HIV vaccine |
-
2014
- 2014-07-09 BR BR112016021692A patent/BR112016021692A2/pt not_active Application Discontinuation
- 2014-07-09 AU AU2014388299A patent/AU2014388299A1/en not_active Abandoned
- 2014-07-09 CA CA2943050A patent/CA2943050A1/en not_active Abandoned
- 2014-07-09 US US15/127,076 patent/US20170165358A1/en not_active Abandoned
- 2014-07-09 SG SG11201607404PA patent/SG11201607404PA/en unknown
- 2014-07-09 SG SG10201808312YA patent/SG10201808312YA/en unknown
- 2014-07-09 MX MX2016012166A patent/MX2016012166A/es unknown
- 2014-07-09 RU RU2016141621A patent/RU2016141621A/ru not_active Application Discontinuation
- 2014-07-09 EP EP14750386.6A patent/EP3122379A1/en not_active Withdrawn
- 2014-07-09 WO PCT/US2014/045940 patent/WO2015147899A1/en not_active Ceased
- 2014-07-09 CN CN201480077507.5A patent/CN106535929A/zh active Pending
- 2014-07-09 JP JP2017502571A patent/JP2017509713A/ja active Pending
- 2014-07-09 KR KR1020167025974A patent/KR20170016315A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170016315A (ko) | 2017-02-13 |
| EP3122379A1 (en) | 2017-02-01 |
| CA2943050A1 (en) | 2015-10-01 |
| JP2017509713A (ja) | 2017-04-06 |
| WO2015147899A1 (en) | 2015-10-01 |
| AU2014388299A1 (en) | 2016-10-20 |
| RU2016141621A3 (enExample) | 2018-05-11 |
| US20170165358A1 (en) | 2017-06-15 |
| RU2016141621A (ru) | 2018-04-25 |
| MX2016012166A (es) | 2017-03-15 |
| SG10201808312YA (en) | 2018-10-30 |
| CN106535929A (zh) | 2017-03-22 |
| SG11201607404PA (en) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| AU2019293244A8 (en) | Personalized cancer vaccine epitope selection | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| MX2022009923A (es) | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. | |
| BR112017011215A2 (pt) | partículas de distribuição de pró-flavorizante | |
| MX389568B (es) | Péptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cáncer de pulmón, que incluye cáncer de pulmón de células no pequeñas (nsclc) | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| WO2016105542A3 (en) | Nanoparticle compositions and methods for immunotherapy | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| EP4056198A3 (en) | Outer membrane vesicles | |
| MA40627A (fr) | Formulations stables de lipides et de liposomes | |
| SG10201900041VA (en) | Meningococcus vaccines | |
| BR112016010205A2 (pt) | ?sistema de vacinação para aplicar vacina para frangas e métodos, dispositivos e montagens associadas?? | |
| MX2021001914A (es) | Peptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celulas no peque?as (nsclc). | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| BR112016021692A2 (pt) | Métodos de preparação de uma composição imunogênica e de aperfeiçoamento de potência imunoestimuladora de vacinas adsorvidas em sal de alumínio, composição imunogênica e uso de uma composição de l(mpla) | |
| MX2018013331A (es) | Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso. | |
| BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| WO2015149016A3 (en) | Breast and ovarian cancer vaccines | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| EA202192380A1 (ru) | Система емкостей и способ приготовления смеси веществ | |
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |